- Home
- MFIN vs VNDA Comparison
MFIN vs VNDA Comparison
Compare MFIN & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- VNDA
- Stock Information
- Founded
- MFIN 1995
- VNDA 2002
- Country
- MFIN United States
- VNDA United States
- Employees
- MFIN N/A
- VNDA N/A
- Industry
- MFIN Finance: Consumer Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- VNDA Health Care
- Exchange
- MFIN Nasdaq
- VNDA Nasdaq
- Market Cap
- MFIN 243.9M
- VNDA 249.4M
- IPO Year
- MFIN 1996
- VNDA 2006
- Fundamental
- Price
- MFIN $9.85
- VNDA $5.27
- Analyst Decision
- MFIN Strong Buy
- VNDA Strong Buy
- Analyst Count
- MFIN 1
- VNDA 2
- Target Price
- MFIN $12.00
- VNDA $16.50
- AVG Volume (30 Days)
- MFIN 33.9K
- VNDA 561.2K
- Earning Date
- MFIN 10-30-2025
- VNDA 11-05-2025
- Dividend Yield
- MFIN 4.85%
- VNDA N/A
- EPS Growth
- MFIN N/A
- VNDA N/A
- EPS
- MFIN 1.75
- VNDA N/A
- Revenue
- MFIN $332,256,000.00
- VNDA $203,467,000.00
- Revenue This Year
- MFIN N/A
- VNDA $15.45
- Revenue Next Year
- MFIN $1.53
- VNDA $37.82
- P/E Ratio
- MFIN $5.65
- VNDA N/A
- Revenue Growth
- MFIN 16.48
- VNDA 11.78
- 52 Week Low
- MFIN $7.71
- VNDA $3.81
- 52 Week High
- MFIN $10.98
- VNDA $5.59
- Technical
- Relative Strength Index (RSI)
- MFIN 46.86
- VNDA 58.91
- Support Level
- MFIN $9.78
- VNDA $5.16
- Resistance Level
- MFIN $10.15
- VNDA $5.54
- Average True Range (ATR)
- MFIN 0.31
- VNDA 0.22
- MACD
- MFIN 0.00
- VNDA -0.01
- Stochastic Oscillator
- MFIN 60.40
- VNDA 61.33
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.